Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of ZL-1310 versus investigator's choice in relapsed small cell lung cancer
CTR20260381Phase 3Active
- Sponsor
- Zai Lab
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zocilurtatug pelitecan in small cell lung cancer (SCLC), sponsored by Zai Lab. Started Mar 2026; status: active.
02
Drugs
zocilurtatug pelitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20260381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260381.